Palliative radiotherapy combined with stent insertion to relieve dysphagia in advanced esophageal carcinoma patients: A systematic review and meta−analysis

Zhiyuan Xu, Haonan Liu, Shengli Li, Zhengxiang Han, Jingjing Chen, Xiangting Liu, Qiang Li, Hong Mu, Jiaqi Yuan, Hailong Lu, Peisheng Jin, Xianliang YanFrontiers in Oncology 2022 · DOI

TL;DR

This systematic review and meta-analysis demonstrates that for patients with advanced esophageal cancer, following up stent insertion with palliative radiotherapy (ROCS) significantly extends median overall survival and improves swallowing ability (dysphagia) compared to stenting alone. Crucially, this combined approach does not appear to increase the risk of major complications like bleeding, pain, or stent migration.

What Problem Does This Paper Address?

Advanced esophageal cancer is notoriously aggressive, often leaving patients with a median survival of only 3 to 6 months. The primary clinical challenge is dysphagia—the inability to swallow—which severely impacts quality of life and nutrition.

The traditional "quick fix" is the insertion of a self-expanding metal stent (SEMS) to mechanically open the esophagus. While effective in the short term, stents don't stop the underlying tumor growth, leading to re-obstruction or complications over time. Palliative radiotherapy is a known alternative, but its slow onset of action makes it less ideal for immediate relief. The authors sought to determine if combining these two—using the stent for immediate relief and radiation to maintain that patency and slow the tumor—actually provides a measurable benefit in survival and quality of life without adding to the patient's burden of side effects.

Methods

The researchers conducted a systematic review and meta-analysis following PRISMA guidelines. They searched five major databases (including PubMed and the Cochrane Library) for studies comparing stenting alone to the combination of stenting plus radiotherapy (referred to as ROCS).

Key methodological features included:

  • Study Selection: They included both Randomized Controlled Trials (RCTs) and observational studies to maximize the data pool.
  • Statistical Modeling: They used Standardized Mean Differences (SMD) for continuous outcomes (like survival and dysphagia scores) and Risk Ratios (RR) for complications.
  • Heterogeneity Assessment: They employed $I^2$ tests to determine whether to use a fixed-effects or random-effects model, ensuring the statistical approach matched the variability of the source data.

Datasets

As a meta-analysis, the "dataset" consists of previously published clinical studies. The authors identified 9 studies meeting their criteria, encompassing a total of 851 patients:

  • 412 patients in the stenting-only group.
  • 439 patients in the ROCS (stenting + radiotherapy) group.

The studies spanned multiple countries (UK, India, USA, China) and included three RCTs and six observational studies.

Key Insights and Ideas

  • The "Synergy" Hypothesis Confirmed: The most significant insight is that radiotherapy acts as a "maintenance" phase for the mechanical intervention. While the stent provides the immediate "opening," the radiation likely delays tumor ingrowth and overgrowth, which are the primary reasons stents eventually fail.
  • Survival Benefit: It is rare for palliative interventions in terminal esophageal cancer to show a significant survival benefit; usually, they only improve quality of life. Finding a significant improvement in median overall survival suggests the combination therapy is more than just a comfort measure.
  • Safety Profile: In oncology, "more treatment" usually equals "more toxicity." Surprisingly, this meta-analysis found no significant difference in bleeding events, stent migration, or pain between the two groups. This suggests that the esophageal tissue tolerates the addition of radiation well, even with a metal stent in place.

Key Results

  • Overall Survival: The ROCS group showed a significantly prolonged median overall survival compared to the stent-only group (SMD: 1.70; 95% CI: 0.67–2.72).
  • Dysphagia Relief: Swallowing scores were significantly better in the ROCS group (SMD: -0.77; 95% CI: -1.02 to -0.51).
  • Complications: There were no statistically significant differences in:
  • Bleeding events (RR: 1.48, $p = 0.246$)
    • Stent migration (RR: 0.80, $p = 0.908$)
    • Pain events (RR: 1.10, $p = 0.141$)

Limitations and Future Work

The authors acknowledge several hurdles that still remain:

  • Small Sample Size: Only nine studies were eligible, and the total patient count (851) is relatively small for a meta-analysis.
  • Heterogeneity: There was significant variation in radiation doses (ranging from 20 Gy to 55 Gy) and the types of stents used across the different studies.
  • Study Age: Some included studies were conducted years ago; advancements in both stent technology and precision radiotherapy (like IMRT) might yield even better results today.
  • Future Direction: The authors call for more large-scale, multi-center RCTs to standardize the "ideal" radiation dose and timing following stent insertion.

Summary updated

Abstract

https://www.crd.york.ac.uk/prospero/, identifier CRD42022337481.
BibTeX
@inproceedings{xu2022palliative,
  author = {Zhiyuan Xu and Haonan Liu and Shengli Li and Zhengxiang Han and Jingjing Chen and Xiangting Liu and Qiang Li and Hong Mu and Jiaqi Yuan and Hailong Lu and Peisheng Jin and Xianliang Yan},
  title = {{Palliative radiotherapy combined with stent insertion to relieve dysphagia in advanced esophageal carcinoma patients: A systematic review and meta−analysis}},
  booktitle = {Frontiers in Oncology},
  year = {2022},
  doi = {10.3389/fonc.2022.986828},
}
Figure